State Street Corp Boosts Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

State Street Corp lifted its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 8.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 817,671 shares of the company’s stock after buying an additional 62,349 shares during the quarter. State Street Corp owned about 2.03% of RxSight worth $40,417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Brown Capital Management LLC purchased a new stake in shares of RxSight in the third quarter worth about $26,813,000. Point72 Asset Management L.P. increased its holdings in RxSight by 610.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after acquiring an additional 384,041 shares during the period. Marshall Wace LLP purchased a new stake in RxSight in the 2nd quarter worth approximately $19,512,000. Driehaus Capital Management LLC boosted its holdings in RxSight by 74.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the period. Finally, Baillie Gifford & Co. grew its position in shares of RxSight by 438.8% during the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after purchasing an additional 291,733 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

RxSight Price Performance

NASDAQ:RXST opened at $33.66 on Friday. RxSight, Inc. has a 1-year low of $33.03 and a 1-year high of $66.54. The business has a 50 day moving average of $45.75 and a 200 day moving average of $50.09. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -40.55 and a beta of 1.11.

Insiders Place Their Bets

In other news, insider Ilya Goldshleger sold 3,105 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $46.08, for a total transaction of $143,078.40. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $1,946,695.68. This trade represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jesse Anderson Corley bought 11,111 shares of the stock in a transaction dated Tuesday, November 12th. The stock was bought at an average cost of $45.37 per share, with a total value of $504,106.07. Following the purchase, the director now owns 468,571 shares in the company, valued at $21,259,066.27. The trade was a 2.43 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 62,707 shares of company stock valued at $3,037,386. 9.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RXST shares. Stifel Nicolaus downgraded RxSight from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $65.00 to $40.00 in a research report on Friday. UBS Group assumed coverage on RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 price target on the stock. Wells Fargo & Company reissued an “equal weight” rating and set a $42.00 price objective (down previously from $56.00) on shares of RxSight in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Finally, Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $59.00.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.